Stocks Health care GPCR
NASDAQ · Health careStructure Therapeutics Inc. (GPCR)
It posted a net loss of $293.9M. In fiscal 2025 capital spending exceeded operating cash flow by $225.8M. At September 30, 2026 it held $222M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on November 9, 2026.
Key facts about Structure Therapeutics Inc.
- Net worth
- Structure Therapeutics Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
- Cash flow
- In fiscal 2025 operations used $222.2M of cash.
- Latest report
- The latest periodic report (quarterly report, 10-Q) was filed with the SEC on November 9, 2026 and covers the period to September 30, 2026. Open on SEC EDGAR
- Next earnings report
- Structure Therapeutics Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
What Structure Therapeutics Inc. does
Structure Therapeutics Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker GPCR.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | n/a | -$141.2M | -$0.80 | -$225.8M |
| 2024 | n/a | -$122.5M | -$0.78 | -$117.9M |
| 2023 | n/a | -$89.6M | -$0.81 | -$81.7M |
| 2023 | n/a | -$51.3M | -$5.51 | -$46.3M |
Earnings: every quarter and the next report date
Full financial statements: income, balance sheet and cash flow
Latest SEC filings
What Structure Therapeutics Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- November 9, 2026
- November 9, 2026
- November 5, 2026Passive stake changed SCHEDULE 13G/A
- September 8, 2026
- August 6, 2026
- August 6, 2026
- August 6, 2026Passive stake changed SCHEDULE 13G/A
- June 18, 2026
- May 7, 2026
- May 7, 2026
Insider trades
What the people running Structure Therapeutics Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.
No insider bought or sold shares on the open market in the last 90 days. The 6 reported changes were pay in shares, option exercises, shares withheld for tax or gifts.
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| September 21, 2026 | Coll Crespo BlasCHIEF MEDICAL OFFICER | Exercised options | 12,024 | - |
| September 18, 2026 | Coll Crespo BlasCHIEF MEDICAL OFFICER | Shares withheld for tax | 10,626 | $124K |
| September 1, 2026 | Lin XichenCHIEF SCIENTIFIC OFFICER | Exercised options | 17,817 | $6.1K |
| September 1, 2026 | Lin XichenCHIEF SCIENTIFIC OFFICER | Exercised options | 17,817 | - |
| August 18, 2026 | Lin XichenCHIEF SCIENTIFIC OFFICER | Exercised options | 11,817 | $4K |
| August 18, 2026 | Lin XichenCHIEF SCIENTIFIC OFFICER | Exercised options | 11,817 | - |
| August 6, 2026 | Berrios John JosephChief Commercial Officer | Received as pay | 140,766 | - |
| August 4, 2026 | Lin XichenCHIEF SCIENTIFIC OFFICER | Exercised options | 11,817 | $4K |
Who owns GPCR
Three views from three kinds of SEC filings, each with its own date. They overlap and are not added up.
5% holders
| Holder | Of class | Filed |
|---|---|---|
| Fmr LLC13G, passive with 1 related filers | 13.2% | August 6, 2026 |
| Wellington Management Group LLP13G, passive with 3 related filers | 10.1% | February 10, 2026 |
| Avoro Capital Advisors LLC13G, passive with 1 related filers | 9.38% | November 14, 2025 |
| Janus Henderson Group PLC13G, passive | 7.7% | November 14, 2025 |
| Deep Track Capital, LP13G, passive with 2 related filers | 5.95% | February 13, 2026 |
Largest institutional holders
Positions that investment managers reported on Form 13F for the quarter ended June 30, 2026, largest first, with the change on the quarter ended March 31, 2026. Managers file 13F up to 45 days after a quarter ends. 192 managers reported a position.
| Holder | Shares | Change on quarter |
|---|---|---|
| Fmr LLC | 7,810,306 | -593,143 |
| Wellington Management Group Llp | 7,379,433 | +119,146 |
| Avoro Capital Advisors LLC | 6,555,555 | 0 |
| Jupiter Topco LLC | 5,204,212 | new |
| Deep Track Capital, LP | 4,740,072 | +460,224 |
| Bvf Inc | 3,366,823 | -92,535 |
| Morgan Stanley | 2,806,640 | +501,183 |
| Orbimed Advisors LLC | 2,209,400 | +733,997 |
| Principal Financial Group Inc | 1,752,753 | -1,011 |
| American Century Companies Inc | 1,682,179 | +244,148 |
| Rtw Investments, LP | 1,607,507 | new |
| Driehaus Capital Management LLC | 1,553,219 | -24,137 |
| Baker Bros. Advisors LP | 1,432,529 | 0 |
| Casdin Capital, LLC | 1,175,000 | 0 |
| Deerfield Management Company, L.P. | 1,086,000 | +318,007 |
| Capitolis Liquid Global Markets LLC | 1,041,100 | -110,200 |
| Siren, L.L.C. | 872,967 | -455,731 |
| Pacific Heights Asset Management LLC | 800,000 | +50,000 |
| Rock Springs Capital Management LP | 640,317 | +100 |
| Aberdeen Group plc | 639,915 | +248,106 |
Insiders
8 insiders reported holding 3,910,921 shares in total, about $85M at the last price.
| Holder | Shares |
|---|---|
| Yoon JunCHIEF FINANCIAL OFFICER | 1,401,656 |
| Stevens Raymond CCHIEF EXECUTIVE OFFICER, Director | 1,401,593 |
| Coll Crespo BlasCHIEF MEDICAL OFFICER | 258,228 |
| Lin XichenCHIEF SCIENTIFIC OFFICER | 228,960 |
| Lang MatthewCOO & GC | 184,614 |
| Hall AshleyChief Development Officer | 155,187 |
| Berrios John JosephChief Commercial Officer | 140,766 |
| Ma YingliCHIEF TECHNOLOGY OFFICER | 139,917 |
Questions about GPCR
What does Structure Therapeutics Inc. do?
Structure Therapeutics Inc. is a company in the Health care sector, listed on NASDAQ as GPCR. Its shares trade on NASDAQ under the ticker GPCR.
What is Structure Therapeutics Inc.'s net worth?
Structure Therapeutics Inc. has a market value (market cap) of $1.5B at the latest share price, and shareholders' equity of $1.2B on its balance sheet at September 30, 2026. A company's "net worth" usually means one of these: what the market pays for all its shares, or its assets minus its liabilities.
Is Structure Therapeutics Inc. profitable?
No. Over the twelve months to September 30, 2026 it reported a net loss of $293.9M.
When did Structure Therapeutics Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on November 9, 2026. It covers the period to September 30, 2026.
When is Structure Therapeutics Inc.'s next earnings report?
Structure Therapeutics Inc.'s next report is expected around February 25, 2027. That is an estimate from its filing rhythm, not a date the company has announced.
Similar companies
Compare GPCR with
Follow GPCR
Get an email when Structure Therapeutics Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Where the numbers come from
Financial figures are the values Structure Therapeutics Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.